Impact of Prior Chemotherapy (CT) and Somatostatin Analogues (SSAs) on Clinical Outcome in Well-Differentiated Pancreatic Neuroendocrine Tumors (pWDNETs) before Treatment of Everolimus (EV) Abstract #732

Introduction: In the phase III RADIANT-3 trial, EV demonstrated a significant improvement in PFS with a median of 11.0 v. 4.6 months (mo) for placebo in pWDNETs pts.
Aim(s): To evaluate the disease control rate (DCR) at first radiologic assessment (8-12 week) defined as the proportion of best radiological response achieved in pts with CR, PR or SD, as a measure of antitumor effect of EV in pWDNETs naïve pts or progressing after CT and/or SSAs.
Materials and methods: We retrospectively analyzed 32 pWDNETs pts treated with EV, between 2009 to 2012 in our Institution.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: dr Sara Pusceddu
Keywords: everolimus

To read results and conclusion, please login ...

Further abstracts you may be interested in

No result